Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

520 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HHV-6 associated diseases are one of the major factors on higher early CNS complications in CB recipients than in those of BM/PBSC.
Kageyama K, Uchida N, Yamamoto H, Takagi S, Ebihara M, Yuasa M, Kaji D, Nishida A, Ishiwata K, Yamamoto G, Asano-Mori Y, Izutsu K, Wake A, Yoneyama A, Makino S, Taniguchi S. Kageyama K, et al. Among authors: yamamoto h, yamamoto g. Bone Marrow Transplant. 2021 Mar;56(3):686-688. doi: 10.1038/s41409-020-01028-5. Epub 2020 Aug 11. Bone Marrow Transplant. 2021. PMID: 32782352 No abstract available.
I.v. BU/fludarabine plus melphalan or TBI in unrelated cord blood transplantation for high-risk hematological diseases.
Yamamoto H, Uchida N, Matsuno N, Kon A, Nishida A, Ota H, Ikebe T, Nakano N, Ishiwata K, Araoka H, Takagi S, Tsuji M, Asano-Mori Y, Yamamoto G, Izutsu K, Masuoka K, Wake A, Yoneyama A, Makino S, Taniguchi S. Yamamoto H, et al. Among authors: yamamoto g. Bone Marrow Transplant. 2015 Apr;50(4):607-9. doi: 10.1038/bmt.2014.316. Epub 2015 Jan 26. Bone Marrow Transplant. 2015. PMID: 25621796 No abstract available.
Anti-HLA antibodies other than against HLA-A, -B, -DRB1 adversely affect engraftment and nonrelapse mortality in HLA-mismatched single cord blood transplantation: possible implications of unrecognized donor-specific antibodies.
Yamamoto H, Uchida N, Matsuno N, Ota H, Kageyama K, Wada S, Kaji D, Nishida A, Ishiwata K, Takagi S, Tsuji M, Asano-Mori Y, Yamamoto G, Izutsu K, Masuoka K, Wake A, Yoneyama A, Makino S, Taniguchi S. Yamamoto H, et al. Among authors: yamamoto g. Biol Blood Marrow Transplant. 2014 Oct;20(10):1634-40. doi: 10.1016/j.bbmt.2014.06.024. Epub 2014 Jun 24. Biol Blood Marrow Transplant. 2014. PMID: 24972251 Free article.
No post-transplant pure red cell aplasia development in 106 major ABO incompatible cord blood transplantation.
Wada S, Asano-Mori Y, Yamamoto H, Yuasa M, Kageyama K, Kaji D, Nishida A, Ishiwata K, Takagi S, Yamamoto G, Uchida N, Yoneyama A, Makino S, Taniguchi S. Wada S, et al. Among authors: yamamoto h, yamamoto g. Bone Marrow Transplant. 2019 May;54(5):765-768. doi: 10.1038/s41409-018-0375-2. Epub 2018 Nov 6. Bone Marrow Transplant. 2019. PMID: 30401968 Clinical Trial. No abstract available.
Splenomegaly Negatively Impacts Neutrophil Engraftment in Cord Blood Transplantation.
Yuasa M, Yamamoto H, Kageyama K, Kaji D, Taya Y, Takagi S, Yamamoto G, Asano-Mori Y, Wake A, Yoneyama A, Makino S, Uchida N, Taniguchi S. Yuasa M, et al. Among authors: yamamoto h, yamamoto g. Biol Blood Marrow Transplant. 2020 Sep;26(9):1689-1696. doi: 10.1016/j.bbmt.2020.05.018. Epub 2020 Jun 4. Biol Blood Marrow Transplant. 2020. PMID: 32505808 Free article.
Prognostic Impact of Cytogenetic Evolution on the Outcome of Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Nonremission: A Single-Institute Analysis of 212 Recipients.
Yuasa M, Yamamoto H, Mitsuki T, Kageyama K, Kaji D, Taya Y, Nishida A, Ishiwata K, Takagi S, Yamamoto G, Asano-Mori Y, Wake A, Koike Y, Makino S, Uchida N, Taniguchi S. Yuasa M, et al. Among authors: yamamoto h, yamamoto g. Biol Blood Marrow Transplant. 2020 Dec;26(12):2262-2270. doi: 10.1016/j.bbmt.2020.08.026. Epub 2020 Aug 29. Biol Blood Marrow Transplant. 2020. PMID: 32871257 Free article.
The impact of graft cell source on bloodstream infection in the first 100 days after allogeneic hematopoietic cell transplantation.
Takagi S, Ogura S, Araoka H, Uchida N, Mitsuki T, Yuasa M, Kageyama K, Kaji D, Taya Y, Nishida A, Kimura M, Ishiwata K, Yamamoto H, Yamamoto G, Asano-Mori Y, Koike Y, Izutsu K, Wake A, Makino S, Yoneyama A, Taniguchi S. Takagi S, et al. Among authors: yamamoto h, yamamoto g. Bone Marrow Transplant. 2021 Jul;56(7):1625-1634. doi: 10.1038/s41409-021-01229-6. Epub 2021 Feb 19. Bone Marrow Transplant. 2021. PMID: 33608659
A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning.
Takagi S, Araoka H, Uchida N, Uchida Y, Kaji D, Ota H, Nishida A, Ishiwata K, Tsuji M, Yamamoto H, Ito T, Matsuno N, Yamamoto G, Asano-Mori Y, Hayashi M, Izutsu K, Masuoka K, Wake A, Makino S, Yoneyama A, Taniguchi S. Takagi S, et al. Among authors: yamamoto h, yamamoto g. Int J Hematol. 2014;99(5):652-8. doi: 10.1007/s12185-014-1529-7. Epub 2014 Mar 25. Int J Hematol. 2014. PMID: 24664791
520 results